Overview

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Lapatinib
Trastuzumab